ArticleMedicines (Basel, Switzerland)2019
Chronic Pruritus Responding to Dupilumab-A Case Series.
Article in Medicines (Basel, Switzerland), 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 40 papers, 3 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
40 citing papers in PubMed, 3 syntheses or guidelines pooled it.
- Efficacy and Safety of Conventional and Biologic Therapies in Prurigo Nodularis: A Systematic Review and Meta-Analysis.International journal of dermatology · 2026Pooled it
- Dupilumab in Inflammatory Skin Diseases: A Systematic Review.Biomolecules · 2023Pooled it
- Dupilumab for the treatment of prurigo nodularis: A systematic review.Frontiers in immunology · 2023Pooled it
- [When the etiology remains unclear: status quo of chronic pruritus of unknown origin].Dermatologie (Heidelberg, Germany) · 2026Article
- Acquired perforating dermatosis associated with uremic pruritus treated with dupilumab monotherapy: A case report.JAAD case reports · 2026Article
- Therapeutic advances in pruritus as a model of personalized medicine.Journal of the European Academy of Dermatology and Venereology : JEADV · 2026Review
- Uremic Pruritus in Hemodialysis: Mechanisms, Burden, and Emerging Therapies.Journal of clinical medicine · 2026Review
- Dupilumab Improves Health-Related Quality of Life in Omalizumab-Naïve Patients with Chronic Spontaneous Urticaria.Dermatology and therapy · 2026Article
- Dupilumab: an Additional Arrow in the Quiver for Prurigo Nodularis? Data From a Real-Life Setting.Dermatology practical & conceptual · 2025Article
- Dupilumab treatment for prurigo nodularis: a retrospective study of 76 patients.Postepy dermatologii i alergologii · 2025Article
- Type 2 Inflammation and Its Role in Dermatologic Diseases.International journal of dermatology · 2025Review
- Eczematous liraglutide eruption managed by dupilumab: A case report.JAAD case reports · 2024Article
- Dupilumab for the treatment of pityriasis lichenoides chronica.JAAD case reports · 2024Article
- Prurigo Nodularis: Pathogenesis and the Horizon of Potential Therapeutics.International journal of molecular sciences · 2024Review
- Combination treatment of dupilumab with bortezomib in a patient with IgG kappa gammopathy of renal significance, uremic pruritus and chronic lichenoid dermatitis.Acta bio-medica : Atenei Parmensis · 2023Article
- Upadacitinib as a treatment for chronic pruritus secondary to polycythemia vera after failure with dupilumab.JAAD case reports · 2023Article
- Neural Regulation of Innate Immunity in Inflammatory Skin Diseases.Pharmaceuticals (Basel, Switzerland) · 2023Review
- Uremic pruritus: pathophysiology, clinical presentation, and treatments.Kidney research and clinical practice · 2023Article
- Dupilumab for Chronic Prurigo: Case Series on Effectiveness, Safety, and Quality of Life.Dermatology (Basel, Switzerland) · 2023Article
- A case of eosinophilic dermatosis of hematologic malignancy with tissue-based Th2 cytokine profiling.JAAD case reports · 2022Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundChronic pruritus is defined as itch lasting for greater than six weeks. Pruritus is a burdensome manifestation of several internal and external disease states with a significant impact on quality of life. Dupilumab has shown promise in treating a number of conditions including atopic dermatitis (AD) and asthma. Its success in reducing pruritus in AD has generated interest regarding its potential application in other pruritic conditions, such as chronic pruritus of unknown origin, uremic pruritus, and pruigo nodularis.
methodsIn this retrospective analysis, we present a series of 20 recalcitrant pruritus patients seen at a tertiary center treated with off-label dupilumab at standard AD dosing.
resultsDupilumab was successful at reducing itch in all treated patients, leading to complete resolution in 12/20 patients and an overall mean NRSi reduction of 7.55. Dupilumab was well tolerated with no significant adverse effects.
conclusionsOur case series suggests dupilumab may be a safe and efficacious therapeutic option in several pruritic conditions and demonstrates the need for further studies to better ascertain its place in the pruritus treatment armamentarium.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.